TScan Therapeutics (NASDAQ:TCRX) Given “Outperform” Rating at Wedbush

Wedbush restated their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research note published on Wednesday,RTT News reports. They currently have a $7.00 price target on the stock.

TCRX has been the subject of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of TScan Therapeutics in a report on Wednesday, December 11th. Needham & Company LLC reduced their target price on shares of TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, TScan Therapeutics presently has a consensus rating of “Buy” and an average target price of $9.20.

TScan Therapeutics Stock Down 4.8 %

TScan Therapeutics stock opened at $1.98 on Wednesday. The firm has a market capitalization of $105.67 million, a PE ratio of -1.87 and a beta of 0.91. The company’s 50-day moving average is $2.43 and its 200-day moving average is $4.04. TScan Therapeutics has a fifty-two week low of $1.82 and a fifty-two week high of $9.69. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.02). The firm had revenue of $0.67 million for the quarter, compared to analyst estimates of $1.43 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. Sell-side analysts anticipate that TScan Therapeutics will post -1.12 earnings per share for the current year.

Institutional Trading of TScan Therapeutics

Several large investors have recently made changes to their positions in TCRX. China Universal Asset Management Co. Ltd. acquired a new stake in shares of TScan Therapeutics during the 4th quarter worth approximately $32,000. Prudential Financial Inc. acquired a new stake in shares of TScan Therapeutics during the 4th quarter worth approximately $32,000. ProShare Advisors LLC acquired a new stake in shares of TScan Therapeutics during the 4th quarter worth approximately $40,000. Wells Fargo & Company MN boosted its position in shares of TScan Therapeutics by 41.1% during the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock worth $59,000 after acquiring an additional 5,694 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of TScan Therapeutics during the 4th quarter worth approximately $59,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.